Search

everythinglearnresearchcommunity

for

Search:↓

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Baricitinib is the most effective treatment for alopecia areata.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

A molecule called α-ketobutyrate was found to extend lifespan and improve aging-related symptoms in worms and mice by activating certain cellular pathways and may help develop anti-aging treatments for humans.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

Mitochondrial features can predict colorectal cancer outcomes and improve immunotherapy.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

AMPK activation may reduce melanoma risk in red-haired individuals.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Baricitinib shows promise for treating alopecia areata with mild side effects.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

The drug combination was safe and showed promise in treating advanced tumors.

New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

MPA increases cancer spread by boosting Eph A2 activity.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Ritlecitinib is an effective new treatment for Alopecia Areata.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.

Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Nilotinib can cause keratosis pilaris, a skin condition.